Actively Recruiting
Study of Gut Microbiota and Immune Function in Patients with Monoclonal Gammopathy and Infection
Led by Zhujiang Hospital · Updated on 2024-09-19
300
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the relationship between the gut microbiota and immune function in patients with monoclonal gammopathy, a condition that can lead to multiple myeloma, especially when complicated by infections. This observational study includes 200 patients diagnosed by MALDI-TOF MS, half of whom have infections, along with 100 healthy individuals matched by age and gender. The goal is to understand how changes in gut bacteria and immune markers relate to infection risks in these patients. Participants are grouped into monoclonal gammopathy patients with infections, without infections, and healthy controls. Researchers will analyze blood and stool samples to compare gut microbiota composition and immune function indicators, such as immune cell profiles and cytokine levels. The study uses a retrospective cohort design to explore these correlations, aiming to provide insights for future prevention and treatment of infections in monoclonal gammopathy. During the study, participants provide blood, plasma, and stool samples, and their clinical data are reviewed. Researchers will assess microbiome changes, immune function, M-protein presence, and metabolic profiles over 24 months. The study involves careful monitoring of infection markers and immune status to better understand disease progression and immune balance in these patients.
CONDITIONS
Brief Title
Intestinal Flora and Immunity in Monoclonal Gammopathy Patients
Research Team
N
Nianyi Zeng
H
Hongwei Zhou, Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here